(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 115.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.41%.
Phathom Pharmaceuticals's revenue in 2025 is $55,252,000.On average, 3 Wall Street analysts forecast PHAT's revenue for 2025 to be $11,689,261,784, with the lowest PHAT revenue forecast at $11,458,067,044, and the highest PHAT revenue forecast at $11,969,898,773. On average, 3 Wall Street analysts forecast PHAT's revenue for 2026 to be $24,399,819,370, with the lowest PHAT revenue forecast at $22,732,988,857, and the highest PHAT revenue forecast at $25,528,913,202.
In 2027, PHAT is forecast to generate $38,804,505,163 in revenue, with the lowest revenue forecast at $36,644,366,353 and the highest revenue forecast at $42,153,347,050.